Binding and functional comparisons of two types of tumor necrosis factor antagonists.
暂无分享,去创建一个
Xiao-Yu Song | B. Scallon | D. Shealy | A. Rosenberg | C. Wagner | Ann Cai | Xiao-yu Song | Carrie Wagner | Bernie Scallon | Ann Cai | Nancy Solowski | Amy Rosenberg | David Shealy | Nancy L. Solowski
[1] P. Mease,et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.
[2] U. Chaudhari,et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.
[3] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[4] R. Gentz,et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. , 1992, Immunology.
[5] L. Gooding,et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.
[6] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[7] R. Cotran,et al. Identification of an inducible endothelial-leukocyte adhesion molecule. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Opal,et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.
[9] D. Kioussis,et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.
[10] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[11] C A Smith,et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.
[12] B. Beutler,et al. The tumor necrosis factor ligand and receptor families. , 1996, The New England journal of medicine.
[13] B. Echtenacher,et al. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.
[14] A. Meager. A cytotoxicity assay for tumour necrosis using a human rhabdomyosarcoma cell line , 1991 .
[15] Joseph Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .
[16] J. Naismith,et al. TNFα and the TNF receptor superfamily: Structure‐function relationship(s) , 2000, Microscopy research and technique.
[17] H. Loetscher,et al. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram- negative sepsis , 1994, The Journal of experimental medicine.
[18] B. Scallon,et al. TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells. , 1994, Cytokine.
[19] D. Banner,et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.
[20] S. Targan,et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. , 2001, Gastroenterology.
[21] C. Smith,et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. , 1990, Science.
[22] J. Richert,et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.
[23] G. Wong,et al. Molecular cloning and expression of a receptor for human tumor necrosis factor , 1990, Cell.
[24] G. Kollias,et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.
[25] Alcocer‐Varela,et al. Interleukin‐8, Interleukin‐10, Intercellular Adhesion Molecule‐1 and Vascular Cell Adhesion Molecule‐1 Expression Levels are Higher in Synovial Tissue from Patients with Rheumatoid Arthritis than in Osteoarthritis , 1999, Scandinavian journal of immunology.
[26] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.
[27] Richard W. Martin,et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.
[28] G. Kollias,et al. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. , 1996, Journal of inflammation.
[29] Samir A. Shah,et al. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. , 1998, Gastroenterology.
[30] M. Feldmann,et al. INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.
[31] G. Kollias,et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. , 1995, Cytokine.
[32] B. Scallon,et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .
[33] M. Feldmann,et al. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[35] R. Jordan,et al. Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation. , 2002, The Journal of infectious diseases.
[36] A. Corti,et al. Oligomeric tumour necrosis factor α slowly converts into inactive forms at bioactive levels , 1992 .
[37] B. Scallon,et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.
[38] A. Zinsmeister,et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.
[39] A. Meager,et al. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. , 1988, Clinical and experimental immunology.